Full-text search across primary regulatory records, analytical lab audits, and evidence-led pharmacology guides.
News WireOn August 12, 2026, Eli Lilly sued Aesthetic Envy, Astra, and four other entities over alleged illegal sales of its investigational obesity drug retatrutide. The company has referred over 200 entities to regulators and flagged 14,000.
News WireFourteen outside advisers split 8-6 to recommend six injectable peptides for compounding pharmacy access, rejecting FDA staff warnings that none has passed rigorous human trials. The non-binding vote aligns with Health Secretary RFK Jr.'s.
News WireEli Lilly filed six federal lawsuits on August 12, 2026, against Aesthetic Envy, Astra, Legendary Peptides, Striker Pharmacy, Texas Peptides, and Lone Star Peptide. The complaints allege these businesses sold illegal versions of.
News WireWeightlifter Jara MacDermott accepted a two-year period of ineligibility on August 20, 2026, for testing positive for canrenone, amphetamine, and testosterone. The announcement arrives eight days after USADA publicly flagged BPC-157 as a.
GuidePepsin and other enzymes dismantle peptides in the stomach within minutes. While oral semaglutide succeeds due to a specific permeation enhancer, standard capsules deliver negligible systemic exposure. This is the core challenge for any.
News WireThe FDA cleared oral semaglutide 25 mg as the first GLP-1 pill for weight loss on December 22, 2025. Truveta data shows the pill drew thousands of new patients into GLP-1 therapy. Eli Lilly's orforglipron awaits FDA review.
GuideNot all peptides are legal in the United States. FDA-approved drugs like insulin are lawful, while unapproved compounds face strict compounding bans. Recent regulatory shifts have created a complex landscape where legality hinges on.
GuideFDA advisers voted to allow compounding pharmacies to produce six unapproved peptides. The decision overrides agency warnings that these products lack human trial data and carry risks of contamination and incorrect dosing.
News WireThe FDA's Pharmacy Compounding Advisory Committee voted 8-6 on July 23 to recommend placing BPC-157, TB-500, and other peptides on the agency's bulks list, a shift that follows years of promotion by Joe Rogan, RFK Jr., and wellness clinic.
News WireThe drugmaker is suing four online peptide sellers, a California med spa, and a compounding pharmacy for marketing an unapproved triple-receptor agonist to consumers under a 'research use' label.
News WireEli Lilly filed six federal lawsuits against compounding pharmacies, med spas, and online sellers marketing unapproved retatrutide as 'research-use only,' challenging a labeling convention the drugmaker says conceals illegal human.
GuideWhile semaglutide and insulin are approved drugs with validated safety data, peptides like BPC-157 and TB-500 are not. Understanding the difference between drug approval and compounding eligibility is critical for patient safety.
GuideOnly three injectable peptide therapies are currently FDA-approved for chronic weight management. This guide distinguishes regulatory status, clinical trial data, and safety profiles for approved therapies versus unregulated research.